VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 25, 2008) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that Dr. Neil Hagen, the lead investigator for WEX's Phase III clinical trial of TTX, will make a presentation titled "Tetrodotoxin (TTX): From Poison to Medicine" at the IXth World Conference on Clinical Pharmacology and Therapeutics in Quebec City, Quebec on July 28. For more information, please see www.cpt2008.com.
